DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.
A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.
The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.
Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.
The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.
Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.
Age ≥18 years ≤ 84
Written informed consent from the participant
Contraindications for MRI (ferrrous material, claustrophobia)
Pregnancy
Diagnosis of primary sclerosing cholangitis (PSC)
Vascular liver disease
Adult patients with liver cirrhosis without prior hepatocellular carcinoma or liver transplant.
Cohort
Prospective
Not listed
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
A nodule on MRI classified as LI-RADS 4 or 5 according to the American College of Radiology (ACR) LI-RADS criteria.
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
A nodule on MRI classified as LI-RADS 4 or 5 according to the American College of Radiology (ACR) LI-RADS criteria.
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
A nodule on MRI classified as LI-RADS 4 or 5 according to the American College of Radiology (ACR) LI-RADS criteria.
Lesion at high risk for hepatocellular carcinoma (HCC) - (LI RADS 4-5)
A nodule on MRI classified as LI-RADS 4 or 5 according to the American College of Radiology (ACR) LI-RADS criteria.
Hepatocellular carcinoma (HCC)
HCC verified by pathology.
Treatment for hepatocellular carcinoma
Treatment given to patients that develope HCC: ablation, resection, TACE, systemic treatment, or best supportive care.
Death
All cause mortality
Liver stiffness (VCTE)
Liver stiffness measured with Fibroscan
Click on the lead sponsor to view all of their trials.
Mattias Ekstedt
Lead sponsor
Linkoeping University
Sponsor institution
Antaros Medical
Collaborator
Amra Medical AB
Collaborator
Region Östergötland
Collaborator
Region Jönköping County
Collaborator
Västra Götalandsregionen
Collaborator
Region Stockholm
Collaborator
Örebro County Council
Collaborator
Uppsala County Council, Sweden
Collaborator
University Hospital, Umeå
Collaborator
